The latest report on “Neuropathic Pain Market (Type – Phantom Limb Pain, Trigeminal Neuralgia, Post Herpetic Neuralgia, and Post-traumatic Neuropathy; Indication – Spinal Stenosis, and Diabetic Neuropathy; Diagnosis – Imaging Physical Examination, and Blood Tests; Treatment – Medication Type, NSAIDs Type, Antidepressant Drugs Type, and Multimodal Therapy; Distribution Channel – Retail Pharmacies and Drug Stores, and Online Pharmacies; End User – Hospitals, and Clinics): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025.” The global neuropathic pain market is projected to grow at a CAGR of 6.1% over the forecast period of 2019-2025.
For More Details Get FREE Sample Pages of this Research Report@ https://www.infiniumglobalresearch.com/reports/sample-request/13297
The increasing occurrence of diabetes and cancer are the major drivers for the growth of the neuropathic pain market across the globe. Diabetes is the most common indication for neuropathic pain followed by cancer. According to the International federation diabetes federation, nearly 420 million adult populations were suffering from diabetes in 2016, and it is increasing at a rate of 8.4% and is expected to reach 625 million by 2040. Furthermore, the increase in the geriatric population also fuels the growth of market growth.
Furthermore, increasing awareness among patients for treatment of neuropathic pain, a rise in the demand for generic drugs, and introduction of new products for the treatment of neuropathic pain are some other factors driving the growth of neuropathic pain market. However, severe side effects of opioids and steroids and increasing prices of branded drugs are some of the factors which may hamper the growth of the global neuropathic pain market. Moreover, strong healthcare infrastructure and well-established reimbursements create an opportunity for the growth of the global neuropathic pain market in the next few years.
North America Holds the Maximum Market Share and is Expected to Dominate the Neuropathic Pain Market
In terms of region, the global market for neuropathic pain has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America holds the maximum market share and is expected to dominate the neuropathic pain market during the forecast period. This is mainly due to a strong distribution network and the presence of advanced healthcare infrastructure and major players in the market in the region.
Furthermore, an increase in the elderly population, which leads to too many disorders and diseases are some other factors that help the growth of the market in the North American region. The European market is estimated to be the second-largest over the forecast period. This is attributed to the increasing cases of cancer patients in the region. The Asia Pacific is estimated to grow at a beneficial rate due to the growing occurrence of diabetes in countries such as China and India.
The report on the global neuropathic pain market covers segments such as type, indication, diagnosis, treatment, distribution channel, and end-user. On the basis of type, the sub-markets include phantom limb pain, trigeminal neuralgia, post herpetic neuralgia, and post-traumatic neuropathy. On the basis of indication, the sub-markets include spinal stenosis, and diabetic neuropathy. On the basis of diagnosis, the sub-markets include imaging physical examination and blood tests.
On the basis of treatment, the sub-markets include medication type, NSAIDs type, antidepressant drugs type, and multimodal therapy. On the basis of the distribution channels, the sub-markets include retail pharmacies and drug stores, and online pharmacies. On the basis of end-user, the sub-markets include hospitals, and clinics.
Browse Detailed TOC and Description of this Exclusive Report@ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-neuropathic-pain-market
The report provides profiles of the companies in the market such as Johnson & Johnson Services Inc., Pfizer Inc., Eli Lily and Company, GlaxoSmithKline PLC, Bristol-Myers Squibb and Company, Sanofi S.A., Biogen Idec Inc., Baxter Healthcare Corporation, and Depomed Inc.
Reasons to Buy this Report:
=> Comprehensive analysis of global as well as regional markets of the neuropathic pain.
=> Complete coverage of all the product type and application segments to analyze the trends, developments, and forecast of market size up to 2025.
=> Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.